Scholarlink

<p>Homozygous carriers of the CNDP1 (CTG)<sub>5</sub> allele with diabetes mellitus are believed to have a lower risk of developing diabetic kidney disease compared to individuals carrying alleles with higher numbers of this CTG repeat. However, recent studies claimed that homozygosity for the (CTG)<sub>5</sub> allele increases the risk of disease progression towards end-stage renal disease and even cardiovascular mortality, at least in women. Therefore, this study sought to confirm in a prospective manner in a cardiovascular high-risk cohort if individuals with two (CTG)<sub>5</sub> alleles indeed have an increased cardiovascular mortality. 3,201 individuals from the LURIC study were included and followed for a median of 9.9 years. CNDP1 (CTG)<sub>n</sub> genotypes were assessed and related to all-cause and cardiovascular mortality. 1,157 (36.1%) patients carried the homozygous CNDP1 (CTG)<sub>5</sub> genotype. No significant difference for all-cause and cardiovascular mortality was detected after multiple adjustments for cardiovascular risk factors, neither for the whole cohort nor for men or women, respectively. In this prospective cardiovascular high-risk cohort, homozygosity for the CNDP1 (CTG)<sub>5</sub> allele was not associated with increased cardiovascular mortality compared to all other genotypes together. These findings do not confirm previous reports suggesting a sex-specific increase in cardiovascular mortality among women carrying two (CTG)<sub>5</sub> alleles.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CNDP1 (CTG)5 allele and cardiovascular events in high-risk patients: LURIC study results

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月21日

查看全文
  • Steffen A. Hettler,
  • Angela Moissl,
  • Graciela E. Delgado,
  • Heyko Skladny,
  • Winfried März,
  • Bernhard K. Krämer,
  • Benito A. Yard,
  • Marcus E. Kleber

摘要

Homozygous carriers of the CNDP1 (CTG)5 allele with diabetes mellitus are believed to have a lower risk of developing diabetic kidney disease compared to individuals carrying alleles with higher numbers of this CTG repeat. However, recent studies claimed that homozygosity for the (CTG)5 allele increases the risk of disease progression towards end-stage renal disease and even cardiovascular mortality, at least in women. Therefore, this study sought to confirm in a prospective manner in a cardiovascular high-risk cohort if individuals with two (CTG)5 alleles indeed have an increased cardiovascular mortality. 3,201 individuals from the LURIC study were included and followed for a median of 9.9 years. CNDP1 (CTG)n genotypes were assessed and related to all-cause and cardiovascular mortality. 1,157 (36.1%) patients carried the homozygous CNDP1 (CTG)5 genotype. No significant difference for all-cause and cardiovascular mortality was detected after multiple adjustments for cardiovascular risk factors, neither for the whole cohort nor for men or women, respectively. In this prospective cardiovascular high-risk cohort, homozygosity for the CNDP1 (CTG)5 allele was not associated with increased cardiovascular mortality compared to all other genotypes together. These findings do not confirm previous reports suggesting a sex-specific increase in cardiovascular mortality among women carrying two (CTG)5 alleles.